gross profit bridgeinconsistent2023-06-30
Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.
Revenue
Unavailable
Fiscal year ended 2026-06-30Operating income
-$9.21M
Fiscal year ended 2026-06-30Free cash flow
Unavailable
Fiscal year ended 2026-06-30Jasper Therapeutics, Inc. (JSPR) reported net income of -$2.76M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Jasper Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Cost of revenue | $3.58M | $3.62M | $6.76M | $9.34M | $15.77M | $9.76M | $13.17M | $8.78M | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | -$9.21M | -$10.95M | -$15.84M | -$19.17M | -$27.08M | -$21.80M | -$25.28M | -$19.89M | -$15.99M | -$15.07M |
| Net income | -$2.76M | -$1.17M | -$9.10M | -$18.74M | -$26.72M | -$21.24M | -$24.32M | -$18.64M | -$14.58M | -$13.73M |
| Research & development | $5.14M | $5.81M | $11.36M | $14.39M | $21.20M | $16.16M | $19.77M | $14.46M | $11.30M | $10.30M |
| Weighted-average diluted shares | shares 28.70M | shares 28.67M | Unavailable | shares 16.64M | shares 15.33M | shares 15.02M | Unavailable | shares 15.00M | shares 14.99M | shares 13.33M |
| Pretax income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Diluted EPS | $-0.10 | $-0.04 | Unavailable | $-1.13 | $-1.74 | $-1.41 | Unavailable | $-1.24 | $-0.97 | $-1.03 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $4.07M | $5.14M | $4.48M | $4.78M | $5.88M | $5.64M | $5.51M | $5.43M | $4.70M | $4.77M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.31M | $14.14M | $28.69M | $50.90M | $39.51M | $48.80M | $71.64M | $92.50M | $106.82M | $118.48M |
| Total assets | $11.80M | $21.18M | $35.78M | $57.47M | $46.47M | $57.60M | $79.90M | $99.41M | $113.93M | $125.96M |
| Current assets | $11.57M | $20.29M | $34.64M | $54.56M | $42.97M | $53.17M | $75.81M | $94.81M | $108.68M | $120.31M |
| Total liabilities | $10.39M | $17.78M | $31.63M | $45.90M | $22.96M | $15.35M | $18.22M | $15.73M | $13.62M | $12.73M |
| Current liabilities | $7.84M | $9.00M | $13.20M | $21.04M | $20.50M | $12.33M | $15.24M | $12.46M | $10.07M | $8.92M |
| Total equity incl. NCI | $1.41M | $3.40M | $4.15M | $11.57M | $23.50M | $42.24M | $61.67M | $83.68M | $100.31M | $113.23M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $2.78M | $2.44M | $6.22M | $9.17M | $8.03M | $3.00M | $4.03M | $3.09M | $2.96M | $2.39M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.92M | -$14.55M | -$21.87M | -$17.00M | -$15.45M | -$22.84M | -$21.13M | -$14.05M | -$11.68M | -$15.74M |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | Unavailable | Unavailable | $0 | $0 | $1.00K | $4.00K | -$76.00K | -$274.00K | -$157.00K | -$25.00K |
| Financing cash flow | Unavailable | Unavailable | -$340.00K | $28.39M | Unavailable | Unavailable | $345.00K | $9.00K | $181.00K | $47.35M |
| Net change in cash | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Stock-based compensation | $764.00K | $423.00K | $1.66M | $1.42M | $1.82M | $1.81M | $1.97M | $2.00M | $1.48M | $1.17M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $21.00K | $21.00K | $290.00K | $229.00K | $258.00K | $279.00K | $245.00K | $500.00K | $300.00K | $288.00K |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Current ratio | 1.47x | 2.26x | 2.62x | 2.59x | 2.10x | 4.31x | 4.98x | 7.61x | 10.79x | 13.49x |
| Revenue YoY growth | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Net margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open JSPR in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-12View SEC filing
Reconciliation checks needing review
4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationinconsistent2023-06-30
Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.
gross profit bridgeinconsistent2023-03-31
Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.
balance equationinconsistent2023-03-31
Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.